Chinese Japanese Germany Korea


Indications and Uses Pharmacokinetics Adverse Reactions Warnings and precautions
Gefitinib structure
Chemical Name:
IRESSA;ZD 1839;Gefinitib;GEFITINIB;Ji Fei Ji;Getfitnib;Gifitinib;AKOS 91371;Gefitinib WS;Gefitinib, >=99%
Molecular Formula:
Formula Weight:
MOL File:

Gefitinib Properties

Melting point:
storage temp. 
Store at RT
white to beige
CAS DataBase Reference
184475-35-2(CAS DataBase Reference)


Safety Statements  24/25

Gefitinib price More Price(4)

Manufacturer Product number Product description CAS number Packaging Price Updated Buy
Cayman Chemical 13166 Gefitinib ≥98% 184475-35-2 1g $238 2018-11-13 Buy
Cayman Chemical 13166 Gefitinib ≥98% 184475-35-2 5g $1056 2018-11-13 Buy
Cayman Chemical 13166 Gefitinib ≥98% 184475-35-2 250mg $66 2018-11-13 Buy
Cayman Chemical 13166 Gefitinib ≥98% 184475-35-2 500mg $125 2018-11-13 Buy

Gefitinib Chemical Properties,Uses,Production

Indications and Uses

Gefitinib is an antineoplastic target therapy drug with relatively high specificity that was developed by the British pharmaceutical company AstraZeneca; it is the first molecular targeted drug to be used in non-small cell lung cancer treatment. Epidermal growth factors (EGF) are a kind of polypeptide with a relative molecular mass of 6.45x103, and they can bind with epidermal growth factor receptors (EGFR) on target cell membrane surfaces to trigger biological effects. EGFR is a type of tyrosine kinase (TK) type receptor, so when bound with EGF, it will promote TK activation in the receptor. This will cause tyrosine residue in the receptor to autophosphorylate and send continuous dividing signals into the cell, causing cell proliferation and differentiation. EGFR is abundant in human tissue, and it is highly expressed in malign tumors. Gefitinib blocks the signal transduction pathway of cell surface EGFR to prevent tumor growth, metastasis, and growth in blood vessels, and it can induce tumor cell apoptosis. Gefitinib is mainly used to treat non-stem cell lung cancer.


It is orally effective, with relatively slow absorption and metabolism following intake. The bioavailability of a single oral 250mg dose is nearly 60%, and its area under curve (AUC) is dependent on dosage. With single daily dosages, blood concentration is steady after 7-10 days, with blood concentration peaking 3-7 hours after medication and then gradually following biphasic reduction (its half-life is 12-58 hours, at an average of 28 hours). It is observed as dose-dependent pharmacokinetics, and following multiple dosages, AUC and Cmax increased proportionally. When taken with food, its Cmax and AUC did not decrease significantly. Its plasma protein binding rate is nearly 90%. Gefitinib is metabolized through many different pathways in the livers in a relatively complicated process; the main component of its oxidative metabolism is the cytochrome P450 enzyme CYP3A4, which mainly metabolizes O-Desmethyl metabolites. Metabolites are unrelated to the pharmacological effects of the original drug. The original drug and many metabolites are mostly passed through the biliary tract and excreted through feces, while the amount of drug excreted through urine is less than 4% the original dosage amount.

Adverse Reactions

Gefitinib is relatively well-tolerated, and most negative reactions are mild and reversible, characteristics that are vastly different from those of standard negative reactions to cytotoxic drugs. Common negative reactions include diarrhea, nausea, rashes, acne, vomiting, and feebleness. Only 1% of patients have had to cease treatment due to negative reactions with an occurrence rate over 20%. There have also been rare cases of acute interstitial pneumonia.

Warnings and precautions

Gefitinib is not suitable for pregnant women, and breastfeeding women should cease breastfeeding throughout their treatment period.

Chemical Properties

Light-Yellow Crystalline Powder


Gefitinib (Iressa, ZD-1839) is an EGFR inhibitor for Tyr1173, Tyr992, Tyr1173 and Tyr992 in the NR6wtEGFR and NR6W cells with IC50 of 37 nM, 37nM, 26 nM and 57 nM, respectively.


Gefitinib is an antineoplastic.


The EGFR or ErbB1 inhibitor gefitinib (Iressa(R), AstraZeneca) was originally approved by the US FDA in 2003 under accelerated regulations for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after progression on docetaxel- and platinum-based chemotherapy. AstraZeneca voluntarily withdrew gefitinib from the market in 2005, owing to failed verification of clinical benefit during post-approval studies. In July 2015, FDA reinstated the approval of gefitinib for a different group of patients (i.e., NSCLC patients with EGFR mutations).
Other approved kinase inhibitors targeting the ErbB family, which includes ErbB1/EGFR, ErbB2/human epidermal growth factor receptor 2 (Her2), ErbB3/ Her3, and ErbB4/Her4, are erlotinib (Tarceva(R), OSI Pharm.), lapatinib (Tykerb(R), GlaxoSmithKline), vandetanib (Caprelsa(R), AstraZeneca), afatinib (Gilotrif(R), Boehringer Ingelheim) , and osimertinib (Tagrisso(R), AstraZeneca). All approved EGFR family inhibitors share a common quinazoline scaffold with the exception of osimertinib, which has a pyrimidinylphenylamine scaffold that resembles that of imatinib and nilotinib. Gefitinib and vandetanib adopt the type I binding mode with “DFG-in” and αC-helix “in” conformation, while erlotinib and lapatinib bind to“DFG-in”with the αC-helix adopting an “out” conformation. Afatinib and osimertinib are covalent inhibitors with an electrophilic enone moiety.

brand name

Iressa (AstraZeneca).

General Description

Geftinib is available as 250-mg tablets for oral administrationin the treatment of NSCLC for those patients who have failedto respond to platinum-based therapies and docetaxel and hasalso been used against squamous cell cancers of the head andneck. The agent is an inhibitor of the TK of EGF-R and possiblyother TKs as well. Gefitinib is both a substrate and inhibitorof Pgp and BCRP. The agent is absorbed slowly afterbeing administered orally with 60% bioavailability.Metabolism occurs in the liver and is mediated primarily byCYP3A4 to give eight identified metabolites resulting fromdefluorination of the phenyl ring, oxidative-O-demethylation,and multiple products arising as a result of oxidation of themorpholine ring. The O-demethylated product represents thepredominate metabolite and is 14-fold less active comparedwith the parent. The parent and metabolites are eliminated inthe feces with a terminal elimination half-life of 48 hours.The drug appears to be well tolerated with the most commonlyreported side effects being rash and diarrhea. It mayalso cause elevations in blood pressure especially in those patientswith preexisting hypertension, elevation of transaminaselevels, and mild nausea and mucositits.

Biological Activity

Orally active, selective inhibitor of EGFR tyrosine kinase (IC 50 = 23-79 nM). Shows minimal activity against ErbB2, KDR, c-flt, PKC, MEK and ERK-2. Blocks EGFR autophosphorylation and inhibits tumor growth in mice bearing a range of human xenografts.

Gefitinib Preparation Products And Raw materials

Raw materials

Preparation Products

Gefitinib Suppliers

Global( 400)Suppliers
Supplier Tel Fax Email Country ProdList Advantage
Frapp's ChemicalNFTZ Co., Ltd.
+86 (576) 8169-6106
+86 (576) 8169-6105 China 887 50
Capot Chemical Co.,Ltd.
+86 (0)571-855 867 18
+86 (0)571-858 647 95 China 19954 60
Shenzhen Sendi Biotechnology Co.Ltd.
0755-23311925 18102838259
0755-23311925 CHINA 3217 55
Henan DaKen Chemical CO.,LTD.
+86-371-55531817 CHINA 22043 58
Beijing Cooperate Pharmaceutical Co.,Ltd.
+86-10-60279497 +86(0)15646567669
+86-10-60279497 CHINA 1530 55
Henan Tianfu Chemical Co.,Ltd.
0371-55170693 CHINA 20786 55
Mainchem Co., Ltd.
+86-0592-6210733 CHINA 32651 55
020-81716319 CHINA 2548 55
Nanjing ChemLin Chemical Industry Co., Ltd.
025-83697070; CHINA 3015 60
Shanghai Yingrui Biopharma Co., Ltd.
+86-21-34979012 CHINA 663 60

View Lastest Price from Gefitinib manufacturers

Image Release date Product Price Min. Order Purity Supply Ability Manufacturer
2018-07-23 Gefitinib
US $100.00 / KG 20KG 97% 20tons career henan chemical co
2018-03-08 Gefitinib
US $20000.00 / KG 10G Min99% 10MT Hubei XinRunde Chemical Co., Ltd.

184475-35-2(Gefitinib)Related Search:

  • Gefitinib N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
  • AKOS 91371
  • n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
  • N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine
  • ZD 1839
  • 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-
  • Ji Fei Ji
  • Gefitinib(TINIBS)
  • 6-(Benzyloxy)-7-methoxyquinazolin-4(3H)-one
  • Gefinitib
  • (3-chloro-4-fluoro-phenyl)-[7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl]amine
  • N-(4-bromo-2-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine
  • Gefitinib, Iressa, ZD1839
  • Getfitnib
  • N-(3-Chloro-4-fluorophenyl)-7-Methoxy-6-(3-Morpholinopropoxy)quinazolin-4-aMine
  • Gifitinib
  • Gefitinib (ZD1839)
  • Gefitinib Tablets
  • 4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-(3-morpholinopropoxy)quinazoline
  • Active Pharmaceutical Ingredients
  • Gefitinib
  • Molecular Targeted Antineoplastic
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Pharmaceutical intermediate
  • APIs
  • Anti-cancer&immunity
  • API
  • Gefitinib WS
  • N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine Gefitinib
  • Gefitinib, >=99%
  • N-(3-Chlor-4-fluorophenyl)-7-[methoxy-6-[(3-morpholin-4-yl)propoxyl]-quinazolin-4-yl]amine
  • Inhibitors
  • Anticancer
  • 184475-35-2
  • C22H24ClFN4O3
Copyright 2017 © ChemicalBook. All rights reserved